Trevi Therapeutics to Participate in Upcoming Conferences
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024 [Yahoo! Finance]